E. David Crawford, MD, presented, “An Overview of RADAR III: Next Generation Imaging,” based on the RADAR III manuscript recently published in The Journal of Urology.
An Overview of RADAR III: Next Generation Imaging – Summary:
E. David Crawford, MD, reviews the history of the efforts of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Working Group. He then provides an update on the recently published RADAR III manuscript, which focuses on the impact of next generation imaging (NGI) on prostate cancer.
Abstract:
The therapeutic options for locally advanced and advanced prostate cancer have increased and improved in the last several years. These therapeutic advancements have led to increased overall survival in both castration-resistant and castration-naive disease. Next generation imaging (NGI) techniques have also impacted diagnostic and therapeutic decision-making. With these changes, clinicians need clarity on the best available information and best practices to treat prostate cancer.
To address this challenge, the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III Group met to offer guidance and develop new guidelines for the use of NGI to stage prostate cancer based on available data and clinical experience. They also discussed the potential impact of NGI modalites on treatment options due to earlier detection of disease.
This presentation reviews the RADAR III manuscript recently published in The Journal of Urology. The RADAR III group recommended NGI techniques for select patients suspected of disease progression. This information is based on clinical judgement and laboratory (biomarker) values, comorbidities, and symptoms.
Ongoing research for additional NGI technologies may offer improved diagnostic accuracy and therapeutic options. As NGI techniques evolve and global accessibility improves, a clinician’s ability to more accurately stage the disease will enhance both decision-making and patient outcomes. We hope you will find this presentation valuable in explaining novel next generation imaging techniques.
The downloadable slide deck for this presentation is also available.
References
Crawford E.D., Koo P.J., Shore N., et al. A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol.2019 Jan 18. [Epub ahead of print].
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.
